M|O|C Cancer Care & Research Centre, India’s largest network of community cancer centres, has raised $18M in funding led by Elevation Capital. Founded in 2018 by four like-minded oncologists; Dr Ashish Joshi, Dr Kshitij Joshi, Dr Pritam Kalaskar and Dr. Vashishth Maniar with a mission of creating an alternate cancer care delivery model that addresses pressing need gaps like proximity, accessibility and affordability in the journey of cancer patients in India. In a statement, Manish Jobanputra, COO, M|O|C Cancer Care & Research Centre said, “Making advanced, effective cancer care accessible to everyone is our top priority. The first investment by Tata Capital Healthcare Fund in 2023 and now the current investment by Elevation Capital significantly propels us forward on this journey. This capital boost will not only enhance our infrastructure and expand the network of taking cancer care closer to the patient but also enable us to conduct large-scale clinical trials, explore new therapies, and maximize the potential of existing ones.”

Over past seven years M|O|C has successfully treated over 4.5 lakh cancer patients with a highly qualified team of 47 oncologists while scaling operations to 23 centres in Mumbai, Pune, Rest of Maharashtra, Ahmedabad, Indore and Chhattisgarh. In the year 2023, M|O|C had successfully raised 10 mn USD from Tata Capital Healthcare Fund to expand and graduate their operations and technological capabilities. India faces a growing cancer burden with 1.5 million new cases annually. However, the cancer care delivery for most patients is woefully inadequate. Current healthcare infrastructures have several limitations in terms of availability of beds per patient, distance that patients travel to the hospital, hygiene and quality of care, lack of personalized care, as well as the premium required to graduate to desired quality of care in private facilities. Most of those are tertiary care centres and by the virtue of their capital-intensive operations, creating a distributed network of facilities dedicated to cancer shall remain a challenge.